# GNS

## Overview
The GNS gene encodes the enzyme glucosamine (N-acetyl)-6-sulfatase, a lysosomal enzyme crucial for the degradation of glycosaminoglycans (GAGs) such as heparan sulfate and keratan sulfate. This enzyme is responsible for the desulfation of 6-sulfated N-acetylglucosamine residues, a key step in the breakdown of these complex carbohydrates within lysosomes (Mok2003Genomic). Proper enzymatic function is essential for cellular waste processing and recycling, maintaining cellular homeostasis and tissue integrity. Mutations in the GNS gene can lead to mucopolysaccharidosis type IIID (MPS IIID), a lysosomal storage disorder characterized by the accumulation of undegraded GAGs, resulting in progressive neurodegeneration and mild somatic symptoms (Jansen2007Sanfilippo; Valstar2010Mucopolysaccharidosis).

## Function
The GNS gene encodes the enzyme N-acetylglucosamine-6-sulfatase, which plays a critical role in the lysosomal degradation of glycosaminoglycans (GAGs), specifically heparan sulfate and keratan sulfate. This enzyme is responsible for desulfating the 6-sulfated N-acetylglucosamine residues, facilitating the breakdown of these complex carbohydrates within lysosomes (Mok2003Genomic). The proper function of N-acetylglucosamine-6-sulfatase is essential for cellular waste processing and recycling, which is crucial for maintaining cellular homeostasis and tissue integrity.

In healthy human cells, the enzyme's activity ensures the efficient degradation of GAGs, preventing their accumulation within lysosomes. This process is vital for normal cellular function and organismal health, as it prevents the development of lysosomal storage disorders. The absence or deficiency of this enzyme leads to the accumulation of undegraded GAGs, resulting in conditions such as mucopolysaccharidosis type IIID (MPS IIID), characterized by progressive neurodegeneration and mild somatic symptoms (Mok2003Genomic).

The enzyme is active within the lysosomal compartment of cells, where it contributes to the breakdown and recycling of cellular components, thus playing a significant role in the maintenance of cellular and tissue health (Mok2003Genomic).

## Clinical Significance
Mutations in the GNS gene, which encodes the enzyme glucosamine (N-acetyl)-6-sulfatase, lead to mucopolysaccharidosis type IIID (MPS IIID), also known as Sanfilippo syndrome type D. This is a rare autosomal recessive lysosomal storage disorder characterized by the accumulation of heparan sulfate due to impaired degradation processes (Jansen2007Sanfilippo; Valstar2010Mucopolysaccharidosis). The clinical manifestations of MPS IIID include progressive mental deterioration, behavioral problems, and motor function decline, with death typically occurring before the third decade of life (Valstar2010Mucopolysaccharidosis). 

Patients with MPS IIID often exhibit severe central nervous system degeneration and relatively mild somatic symptoms. Common issues in patient care include behavioral problems, sleep disturbances, recurrent infections, dysphagia, and orthopedic pain (Jansen2007Sanfilippo). Genetic studies have identified various mutations in the GNS gene, including nonsense, missense, splice site, and frameshift mutations, as well as large deletions, all of which predict protein truncation and loss of enzyme function (Beesley2007Identification; Valstar2010Mucopolysaccharidosis). Despite the identification of these mutations, there is no clear genotype-phenotype correlation (Jansen2007Sanfilippo).


## References


[1. (Beesley2007Identification) Clare E. Beesley, Daniela Concolino, Mirella Filocamo, Bryan G. Winchester, and Pietro Strisciuglio. Identification and characterisation of an 8.7kb deletion and a novel nonsense mutation in two italian families with sanfilippo syndrome type d (mucopolysaccharidosis iiid). Molecular Genetics and Metabolism, 90(1):77–80, January 2007. URL: http://dx.doi.org/10.1016/j.ymgme.2006.07.014, doi:10.1016/j.ymgme.2006.07.014. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2006.07.014)

[2. (Jansen2007Sanfilippo) An C. M. Jansen, Henian Cao, Paige Kaplan, Kenneth Silver, Gabriel Leonard, Linda De Meirleir, Willy Lissens, Inge Liebaers, Martin Veilleux, Frederick Andermann, Robert A. Hegele, and Eva Andermann. Sanfilippo syndrome type d: natural history and identification of 3 novel mutations in thegnsgene. Archives of Neurology, 64(11):1629, November 2007. URL: http://dx.doi.org/10.1001/ARCHNEUR.64.11.1629, doi:10.1001/archneur.64.11.1629. This article has 43 citations.](https://doi.org/10.1001/ARCHNEUR.64.11.1629)

[3. (Mok2003Genomic) Andrea Mok, Henian Cao, and Robert A. Hegele. Genomic basis of mucopolysaccharidosis type iiid (mim 252940) revealed by sequencing of gns encoding n-acetylglucosamine-6-sulfatase. Genomics, 81(1):1–5, January 2003. URL: http://dx.doi.org/10.1016/s0888-7543(02)00014-9, doi:10.1016/s0888-7543(02)00014-9. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0888-7543(02)00014-9)

[4. (Valstar2010Mucopolysaccharidosis) Marlies J. Valstar, Aida M. Bertoli-Avella, Marja W. Wessels, George J.G. Ruijter, Bianca de Graaf, Renske Olmer, Peter Elfferich, Sanne Neijs, Roxana Kariminejad, Fatih Suheyl Ezgü, Aysegul Tokatli, Barbara Czartoryska, Ad N. Bosschaart, Feikje van den Bos-Terpstra, Hugues Puissant, Friederike Bürger, Heymut Omran, D. Eckert, Mirella Filocamo, Emil Simeonov, Patrick J. Willems, Ron A. Wevers, Martinus F. Niermeijer, Dicky J.J. Halley, Ben J.H.M. Poorthuis, and Otto P. van Diggelen. Mucopolysaccharidosis type iiid: 12 new patients and 15 novel mutations. Human Mutation, pages n/a-n/a, 2010. URL: http://dx.doi.org/10.1002/humu.21234, doi:10.1002/humu.21234. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21234)